Reviewer’s report

Title: A Multicenter Phase II Study of Everolimus in Patients with Progressive Unresectable Adenoid Cystic Carcinoma

Version: 2 Date: 8 June 2014

Reviewer: Mark McKeage

Reviewer’s report:

This is a high quality report of a well conducted clinical trial of a therapy previously unstudied in this disease setting. It is suitable for publication as is without revision but could be improved by revision to address the following suggestions

The authors could make mention of myb translocations in adenoid cystic carcinoma and whether or not the resulting aberrant signalling would be suppressed by everolimus.

The authors should comment on whether or not their findings are sufficient for justifying further clinical trials of everolimus in this setting and what the next clinical trial should be.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I have no competing interests